<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205567</url>
  </required_header>
  <id_info>
    <org_study_id>BMT14</org_study_id>
    <nct_id>NCT02205567</nct_id>
  </id_info>
  <brief_title>Bergamot and Cardio-Metabolic Risk Factors</brief_title>
  <official_title>The Effect of Bergamot on Plasma Lipids, Lipoproteins and Carotid Intima-media Thickness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bergamot-derived products have shown significant effects on plasma lipids. We aim in the
      present study to evaluate the effect of bergamot on several cardio-metabolic risk markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research hypothesis is to assess whether bergamot reduces plasma lipids (total
      cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol and high-density
      lipoprotein (HDL)-cholesterol), atherogenic lipoproteins, carotid intima-media thickness
      (IMT) and liver steatosis in patients with dyslipidemia.

      The primary objective is to assess whether bergamot reduces plasma lipids and atherogenic
      lipoproteins in patients with dyslipidemia.

      Primary endpoint: Reduction in plasma lipids and atherogenic lipoproteins. The secondary
      objective is to assess whether bergamot reduces carotid intima-media thickness (IMT) and
      liver steatosis in patients with dyslipidemia.

      Secondary endpoint: Reduction in IMT and and liver steatosis.

      Clinical diagnostic tools will include the measurement of:

        1. cIMT, that will be assessed by B-mode real-time ultrasound using a single sonographer
           (Medison SonoAce Pico, with a probe of 7.5-10.0 MHz) in a standardized manner with fixed
           angles of insonation;

        2. liver steatosis, that will be assessed by by abdominal ultrasound.

      Biochemical analyses will include the analysis of:

        1. Routine testing of plasma lipids;

        2. Atherogenic lipoproteins, e.g. the analysis of 11 distinct lipoproteins including
           very-low-density lipoprotein (VLDL), 3 intermediate density lipoprotein (IDL) subclasses
           and 7 low density lipoprotein (LDL) subclasses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in plasma lipids</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>We will measure at baseline and after 6 months the following plasma lipids concentrations: total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in atherogenic lipoproteins, carotid intima-media thickness (IMT) and liver steatosis</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>We will measure at baseline and after 6 months carotid IMT by color doppler ultrasound, atherogenic lipoproteins by electrophoresis and liver steatosis by abdominal ultrasound.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">160</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>1000 mg/day of Bergamot-derived product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>500 mg/day of Bergamot-derived product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bergamot-derived product</intervention_name>
    <description>Group 1: 500mg/day Group 2: 1000mg/day</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        adult subjects with dyslipidemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elevated LDL-cholesterolemia

        Exclusion Criteria:

          -  severe hepatic or renal diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Montalto, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Palermo, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Manfredi Rizzo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

